India

The acquisition is expected to strengthen Sun Pharma’s global footprint while broadening its presence in women’s health, biosimilars, and established medicines.

The companies are competing for a share of India’s Semaglutide market, which analysts estimate will reach USD1 billion over the next two years.

The merger is set to complete within the next quarter, pending final regulatory and statutory approvals from the National Company Law Tribunal (NCLT).

The partnership will bring select consultant vascular and endovascular surgeons from Sir Ganga Ram Hospital’s IVES to C37’s Dubai facility.

The facility will house sophisticated equipment, including liquid-phase peptide synthesis reactors ranging from 250 to 3,000 liters and solid-phase peptide synthesis reactors up to 500 liters.

This arrangement strengthens an existing partnership between the two pharmaceutical giants, who already collaborate on manufacturing the mpox vaccine.

She will oversee the pharmaceutical company’s operations across India, Bangladesh, Nepal, Sri Lanka, and Maldives while joining the Board of Boehringer Ingelheim India.

Novartis will continue operating its subsidiary Novartis Healthcare Private Limited, which serves as the commercial arm for the company’s operations in India.

Once fully operational, the manufacturing plant is expected to create direct employment opportunities for more than 500 people.

The World Health Organization has listed Nipah among its top ten priority diseases alongside pathogens like Covid-19 and Zika due to its potential to trigger epidemics.